Summary
President Donald Trump, Eli Lilly, and Novo Nordisk announced a plan to lower the cost of GLP-1 weight-loss drugs for Medicare and Medicaid, as well as cash-paying customers. This agreement aims to make these treatments more affordable and accessible, particularly for older adults and low-income individuals who receive government healthcare. The new pricing will start at $149 per month for Medicare and Medicaid patients, with further benefits for commercial insurers and cash payers.
Key Facts
- President Trump, Eli Lilly, and Novo Nordisk announced a deal to reduce prices of GLP-1 weight-loss drugs.
- The lower prices will apply to Medicare and Medicaid and cash-paying customers.
- Medicare patients will pay $149 per month for new weight-loss pills once approved.
- Injectable GLP-1 drug prices will start at $245 per month for Medicare and Medicaid patients.
- TrumpRx, a new platform, will offer these drugs starting at or below $350 monthly, reducing to $245 within two years.
- Commercial insurers will access prices 25% lower than current rates.
- The price changes will take full effect by mid-2026 for Medicare and Medicaid patients.
- Eli Lilly and Novo Nordisk will receive tariff relief and fast-track vouchers for some future drugs.
